A Phase 1/2, Single-Arm Study To Assess The Efficacy and Safety Of 48-Hour Continuous Intravenous Dosing Of ON 01910.Na Administered Once a Week for 3 Weeks of a 4-Week Cycle in Patients With Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML).

Trial Profile

A Phase 1/2, Single-Arm Study To Assess The Efficacy and Safety Of 48-Hour Continuous Intravenous Dosing Of ON 01910.Na Administered Once a Week for 3 Weeks of a 4-Week Cycle in Patients With Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Rigosertib (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Sponsors Onconova Therapeutics
  • Most Recent Events

    • 05 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 16 Apr 2013 Planned end date changed from 1 Mar 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.
    • 25 Jan 2013 Planned end date changed from 1 Oct 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top